In June 2007, European hedge fund, GLG Partners, went public through a $3.4 billion reverse-merger transaction. It was an overwhelmingly successful venture for GLG, but an even more notable event in the special purpose acquisition (SPAC) marketplace. Paul Broude, a partner in Foley’s Boston office and member of the Transactional & Securities Practice, was quoted in the August 2007 issue of Mergers & Acquisitions Journal in the article “SPAC Invaders” as saying that this is a sign of things to come. The SPAC transaction is gaining more respect and the GLG deal only adds momentum to this emerging trend.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”